CareDx Q4 revenue $86.6M (+32% YoY), FY2025 guidance $365-375M; $50M buyback

CareDx, Inc.

2024-FY EPS reported $0.93 revenue$333,785,000

Q4 revenue $86.6M (+32% YoY); testing services revenue $63.8M (+37%); volume ~45,500 tests (+14%).
Q4 GAAP net income $87.7M ($1.51 diluted EPS) vs loss $118.1M in Q4 2023; non-GAAP net income $10.7M ($0.18).
Full year revenue $333.8M (+19%); net income $52.5M (incl. $96.3M litigation reversal); adj. EBITDA $27.8M.
Board authorized $50M stock buyback over up to 24 months. Cash $261M, no debt as of Dec 31, 2024.
FY2025 revenue guidance $365M-$375M (9-12% growth); CEO cites 'transformative year' and long-term growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.